Key result
The cTnI assay is currently the most sensitive and specific marker for cardiac damage in acute myocardial infarction, replacing older, less specific cardiac markers.
Why the study?
Does the cTnI assay provide a more sensitive and specific early diagnosis of cardiac damage in acute MI compared to older cardiac markers?
Does the cTnI assay provide a more sensitive and specific early diagnosis of cardiac damage in acute MI compared to older cardiac markers?
The cTnI assay is highlighted as the superior, most sensitive and specific biomarker for the early diagnosis of acute myocardial infarction, replacing legacy cardiac markers.
The troponin assay is the "new kid on the block." cTnI is currently the most sensitive, specific marker for cardiac damage and will replace the other less specific cardiac markers. This is a result of continued search for measures that provide the earliest diagnosis, which in turn ensures the greatest positive influence on morbidity and mortality in acute MI. Is the cTnI assay the ultimate marker for cardiac injury? It is doubtful. Only time will tell.
No takes yet. Share an insight, caveat, or question.
Futterman et al. (1997) conducted a review in Acute myocardial infarction. cTnI assay vs. Other cardiac markers was evaluated on Diagnosis of cardiac damage. The cTnI assay is currently the most sensitive and specific marker for cardiac damage in acute myocardial infarction, replacing older, less specific cardiac markers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: